Symphony Capital, LLC
875 Third Avenue
New York, NY 10022
USA
Telephone + 1.212.632.5400
Fax: + 1.212.632.5401
Email: mark@symphonycapital.com
Mr. Kessel co-founded Symphony in January 2002 and is widely recognized as one of the innovators in structuring product development investments for the pharmaceutical industry. Mr. Kessel was formerly the Managing Partner of Shearman & Sterling, with day-to-day operating responsibility for one of the leading international law firms. Mr. Kessel became a Partner at Shearman & Sterling in 1977 and managed the San Francisco office from 1979 to 1990. Throughout his career he has been a leading advisor to companies and investment banking firms pursuing mergers and acquisitions and public and private offerings of equity and debt securities. Mr. Kessel has published extensively on corporate governance, the role of audit committees and related issues.
He received a B.A. degree with honors in Economics from the City College of New York and a J.D. degree magna cum laude from Syracuse University College of Law. Mr. Kessel is currently a director of and Vice Chairman of the Global Alliance for TB Drug Development, a member of the Emerging Companies Section of the Biotechnology Industry Organization and has served on the Board of Directors of Heller Financial, Inc. and as Chairman of its Audit Committee until its acquisition by GE Capital, Antigenics, Inc. and Harrods (UK) Ltd. and the Board of Advisors of Syracuse University College of Law.